share_log

BMO Capital Maintains Outperform on Candel Therapeutics, Lowers Price Target to $3

BMO Capital Maintains Outperform on Candel Therapeutics, Lowers Price Target to $3

BMO Capital维持Candel Therapeutics跑赢大盘,将目标股价下调至3美元
Benzinga ·  2023/05/15 08:31

BMO Capital analyst Evan David Seigerman maintains Candel Therapeutics (NASDAQ:CADL) with a Outperform and lowers the price target from $9 to $3.

BMO Capital分析师埃文·戴维·塞格曼维持Candel Therapeutics(纳斯达克股票代码:CADL)的跑赢大盘,并将目标股价从9美元下调至3美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发